Form 144 Moderna For: 23 February
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Moderna Inc (MRNA)
Get information about the Moderna Stock. Find more details on MRNA stock to help you take informed decisions by going to one of the sections under this page - from Moderna stock price historical data, price charts, technical analysis, and news to the balance sheet. Find Moderna quotes in the main stock markets such as NASDAQ and Mexico.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
48.68
54.02
52 wk Range
22.28
55.20
MRNA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
48.6854.02
52 wk Range
22.2855.20
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MRNA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
42.05
Downside
-16.40%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
4 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Moderna Inc Company Profile
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax , mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Moderna Inc SWOT Analysis
mRNA Pioneer's Pivot | Explore Moderna's transition from COVID-19 success to a diversified biotech powerhouse, facing challenges in profitability and market adaptation |
Pipeline Potential | Delve into Moderna's robust pipeline, including next-gen COVID-19 vaccines, RSV treatments, and promising oncology therapies shaping its future |
Financial Crossroads | Analysts project EPS of -9.97 for FY1 and -6.17 for FY2, with price targets ranging from $28 to $45, reflecting Moderna's complex financial landscape |
Strategic Evolution | Learn how Moderna aims to break even by 2028 through cost-cutting measures and leveraging its mRNA platform across multiple therapeutic areas |
Moderna Inc Earnings Call Summary for Q4/2025
- Moderna reported Q4 2025 EPS of -2.11 and revenue of $678M, beating forecasts of -2.62 and $662.84M respectively, driving a 3.99% pre-market stock increase.
- Despite 2025 net losses of $2.8B, the company projects up to 10% revenue growth in 2026 with year-end cash and investments between $5.5-6B against $4.2B in projected costs.
- CEO Stéphane Bancel attributed the $1.9B annual revenue to Spikevax and mNEXSPIKE sales, emphasizing ongoing cost reduction initiatives alongside growth strategies.
- Key challenges include FDA's refusal to file for the flu vaccine, continued net losses, competitive pressures, and potential market saturation in key regions.
Last Updated: 2026-02-13, 09:26 a/m
Read Full TranscriptCompare MRNA to Peers and Sector
Metrics to compare | MRNA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMRNAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.0x | −9.2x | −0.6x | |
PEG Ratio | −0.33 | 0.02 | 0.00 | |
Price/Book | 2.3x | 2.8x | 2.6x | |
Price / LTM Sales | 10.2x | 7.0x | 3.3x | |
Upside (Analyst Target) | −28.9% | 45.3% | 45.0% | |
Fair Value Upside | Unlock | −1.1% | 5.9% | Unlock |
Analyst Ratings
4 Buy
17 Hold
3 Sell
Ratings:
24 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 42.05
(-16.40% Downside)
Earnings
Latest Release
Feb 13, 2026
EPS / Forecast
-2.11 / -2.62
Revenue / Forecast
678.00M / 662.84M
People Also Watch
FAQ
What Is the Moderna (MRNA) Stock Price Today?
The Moderna stock price today is 50.30
What Stock Exchange Does Moderna Trade On?
Moderna is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Moderna?
The stock symbol for Moderna is "MRNA."
What Is the Moderna Market Cap?
As of today, Moderna market cap is 19.95B.
What Is Moderna's Earnings Per Share (TTM)?
The Moderna EPS (TTM) is -7.25.
When Is the Next Moderna Earnings Date?
Moderna will release its next earnings report on Apr 30, 2026.
From a Technical Analysis Perspective, Is MRNA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Moderna Stock Split?
Moderna has split 0 times.
How Many Employees Does Moderna Have?
Moderna has 4700 employees.
What is the current trading status of Moderna (MRNA)?
As of Feb 23, 2026, Moderna (MRNA) is trading at a price of 50.30, with a previous close of 49.87. The stock has fluctuated within a day range of 48.68 to 54.02, while its 52-week range spans from 22.28 to 55.20.
What Is Moderna (MRNA) Price Target According to Analysts?
The average 12-month price target for Moderna is USD42.05, with a high estimate of USD135 and a low estimate of USD12. 4 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Neutral. The stock has an -16.40% Downside potential.
What Is the MRNA Premarket Price?
MRNA's last pre-market stock price is 48.72. The pre-market share volume is 77,860.00, and the stock has decreased by -1.15, or -2.31%.
What Is the MRNA After Hours Price?
MRNA's last after hours stock price is 50.27, the stock has decreased by -0.02, or -0.04%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.